Wedbush analyst Laura Chico maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $16.48.
Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Pharvaris, and Travere Therapeutics. According to TipRanks, Chico has an average return of 1.8% and a 46.57% success rate on recommended stocks.
Edgewise Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $30.26.
EWTX market cap is currently $1.53B and has a P/E ratio of -10.49.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is neutral on the stock. Most recently, in February 2024, John R. Moore, the GC of EWTX sold 29,835.00 shares for a total of $596,700.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edgewise Therapeutics (EWTX) Company Description:
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
